Cerus Corp CERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CERS is a good fit for your portfolio.
News
-
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
-
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
-
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
-
Cerus Corporation Celebrates World Blood Donor Day 2024
-
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
-
Cerus Corporation Announces First Quarter 2024 Financial Results
-
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
Trading Information
- Previous Close Price
- $2.38
- Day Range
- $2.33–2.46
- 52-Week Range
- $1.21–3.08
- Bid/Ask
- $2.38 / $2.56
- Market Cap
- $440.04 Mil
- Volume/Avg
- 735,800 / 964,890
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.63
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.04%
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 280
- Website
- https://www.cerus.com
Comparables
Valuation
Metric
|
CERS
|
NVAX
|
06660
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 26.05 |
Price/Book Value | 8.91 | — | 1.93 |
Price/Sales | 2.63 | 2.46 | 5.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
CERS
NVAX
06660
Financial Strength
Metric
|
CERS
|
NVAX
|
06660
|
---|---|---|---|
Quick Ratio | 1.65 | 0.62 | 0.74 |
Current Ratio | 2.41 | 0.90 | 0.95 |
Interest Coverage | −2.48 | −26.84 | −51.05 |
Quick Ratio
CERS
NVAX
06660
Profitability
Metric
|
CERS
|
NVAX
|
06660
|
---|---|---|---|
Return on Assets (Normalized) | −6.40% | −20.87% | −3.57% |
Return on Equity (Normalized) | −24.66% | — | −6.57% |
Return on Invested Capital (Normalized) | −3.88% | — | −4.09% |
Return on Assets
CERS
NVAX
06660
Medical Devices Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Abbott Laboratories
ABT
| Bgmrdrqxt | Ybpdskg | $183.1 Bil | |||
Stryker Corp
SYK
| Bzbvbjvfb | Kwkd | $126.3 Bil | |||
Boston Scientific Corp
BSX
| Dqwbxdtj | Vgnysc | $109.2 Bil | |||
Medtronic PLC
MDT
| Tsyvbjh | Lxzkhz | $100.6 Bil | |||
Edwards Lifesciences Corp
EW
| Wbzxrbvrjh | Yhrqdt | $36.0 Bil | |||
DexCom Inc
DXCM
| Vvvhrgqkll | Fgjs | $25.6 Bil | |||
Koninklijke Philips NV ADR
PHG
| Grxvdjxk | Mgmgppl | $24.3 Bil | |||
Steris PLC
STE
| Lbbgfxsvq | Dcjtqsz | $23.0 Bil | |||
Zimmer Biomet Holdings Inc
ZBH
| Sxljfyjhz | Mfjkp | $22.8 Bil | |||
Align Technology Inc
ALGN
| Hrslkgzdk | Bfvxd | $16.6 Bil |